In this articleMTSRNOVO.B-DKPFEwatch nowA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday. As of now, Metsera says that Novo Nordisk's up to $10 billion offer for the company is "superior" to Pfizer's new proposal. ...

Novo Nordisk is out with results this morning now lowering its fullear profit uh and revenue uh forecast. Meanwhile, uh the company it's it's getting very interesting in terms uh of uh this possible uh bidding war uh that uh that we are seeing as we move that up a little bit please. That's what this means.Yeah, there you go. Keep going. Keep going. Keep going.Joining us now, Novo Nordis CEO Mike Dudstar. It's good to have you on. Uh can we talk uh about how much this is uh cherished this company met very sm ...

We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Tuesday. Metsera rallied to a new all-time high on Tuesday after pharmaceutical giant Novo Nordisk heated up efforts to snatch the company from Pfizer Inc. for an upsized $10 billion acquisition offer. In intra-day trading, Metsera, Inc. (NASDAQ:MTSR) jumped to a new 52-week high of $74.24 before trimming gains to finish the day just up by 20.50 percent at $73.18 ap ...

Management lowers full-year guidance, warns about competition, launches bid for Metsera. ...

Thank you Karen indeed Magdusta joining us now for a chat here in the HQ of nominisk so much news from for you you've been in a job just from 12 weeks so let's just dive in straight away let's start with the results the Q3 results uh you cut your guidance uh once again for the rest of the year so just can you flesh out for us how challenging are things particularly in the US market >> sure when you look at the overall numbers for the first nine months then you would say 15% sales growth 10% operating profit ...

点击蓝字，关注我们 今日上午港股 1 . 中国 中免(01880)逆市 涨超3.9% 。消息面上，中国中免近期宣布首次中期分红计划，拟每10股派 现2.50 元（含税），合计派发约5.17 亿元，占前三季度归母净利润的16.95%。 2. 古茗(01364)早盘涨近4%，截至发稿，涨1.39% 。消息面上，古茗控股发布公告称，将于2025年11 月14日（星期五）召开董事会会议，主要议程包括考虑及批准宣派特别股息事项。 3. 越疆(02432)逆势涨超4.38% 。消息面上，11月4日晚，越疆机器人公众号发文称，蓝思科技与越疆 科技正式达成深度战略合作，以1000台机器人采购订单与持续深化合作层次承诺为核心，标志着双方 战略伙伴关系进入规模化、全方位的新阶段，共同致力于为全球工业智能化升级树立领先标杆。 4. 天立国际控股(01773)涨超4.4% 。消息面上，10月28日，四川省基础教育"网链共享计划"·成都 市"人工智能+教学"应用场景建设推进会暨青羊区"人工智能+教育"主题研讨活动在成都成功举办。 5. 亿华通(02402)再涨超近8% 。消息面上，亿华通此前发布业绩，前三季度公司经营活动现金流净额 为 ...

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50. • Watch the MTSR momentum here.Metsera said the amended proposal constitutes a “Superior Company Proposal.”Additionally, Metsera would issue Novo Nordisk non-voting preferred stock representing 50% of Metsera’s share capital.On the same day, Metsera would declare a dividend of $62.20 per share in cash (up from $56.50).Metsera shareholders co ...

Metsera stock (NASDAQ: MTSR) surged roughly 20% on Tuesday after the obesity-focused biotech announced that Novo Nordisk's revised $10 billion acquisition proposal has been deemed "superior†to Pfizer... ...

We got an oldfashioned bidding war going on between Nova Nordisk and Fizer to take control of Metsera. Our viewers may remember it was last week or actually a few weeks ago Fizer had a deal to acquire this company to try to build its presence uh in the GLP1 arena essentially uh reducing obviously people's uh weight um where it really has not had a great deal of success going up against the incumbents Eli Liy and Nova Nordis. But then Novo came in last week with an interesting offer in terms of its structure ...

TESLA WATCH: Elon Musk Pay Deal In Focus Novo Nordisk (NVO) said it would pay up to $10 billion to acquire obesity-focused Metsera (MTSR), topping Pfizer's (PFE) recently hiked $8.1 billion proposal. The news sent Metsera stock flying more than 15% to 70. Meanwhile, Pfizer stock rose a fraction, while Novo shares gained 1.2%. Pfizer and Metsera have been locked in a heated battle over the last week to buy Metsera. Pfizer's first bid, in September, was for $4.9 billion. Last week, Novo Nordisk made an unsoli ...